- Home
- VFL vs CHRS Comparison
VFL vs CHRS Comparison
Compare VFL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFL
- CHRS
- Stock Information
- Founded
- VFL 1993
- CHRS 2010
- Country
- VFL United States
- CHRS United States
- Employees
- VFL N/A
- CHRS N/A
- Industry
- VFL Finance/Investors Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VFL Finance
- CHRS Health Care
- Exchange
- VFL Nasdaq
- CHRS Nasdaq
- Market Cap
- VFL 117.3M
- CHRS 112.5M
- IPO Year
- VFL N/A
- CHRS 2014
- Fundamental
- Price
- VFL $9.62
- CHRS $0.78
- Analyst Decision
- VFL
- CHRS Buy
- Analyst Count
- VFL 0
- CHRS 3
- Target Price
- VFL N/A
- CHRS $4.68
- AVG Volume (30 Days)
- VFL 38.0K
- CHRS 1.5M
- Earning Date
- VFL 01-01-0001
- CHRS 05-12-2025
- Dividend Yield
- VFL 4.16%
- CHRS N/A
- EPS Growth
- VFL N/A
- CHRS N/A
- EPS
- VFL N/A
- CHRS N/A
- Revenue
- VFL N/A
- CHRS $272,251,000.00
- Revenue This Year
- VFL N/A
- CHRS N/A
- Revenue Next Year
- VFL N/A
- CHRS $19.78
- P/E Ratio
- VFL N/A
- CHRS N/A
- Revenue Growth
- VFL N/A
- CHRS 19.87
- 52 Week Low
- VFL $7.93
- CHRS $0.66
- 52 Week High
- VFL $10.77
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- VFL 38.23
- CHRS 41.87
- Support Level
- VFL $9.67
- CHRS $0.74
- Resistance Level
- VFL $9.84
- CHRS $0.82
- Average True Range (ATR)
- VFL 0.11
- CHRS 0.06
- MACD
- VFL -0.02
- CHRS -0.00
- Stochastic Oscillator
- VFL 9.09
- CHRS 39.13
About VFL abrdn National Municipal Income Fund
Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund seeks to provide current income exempt from regular federal income tax consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, Delaware Funds by Macquarie Premier Models, Managed accounts, Closed-end funds, and Variable Insurance Products.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.